- Home
- MCRB vs RITR Comparison
MCRB vs RITR Comparison
Compare MCRB & RITR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- RITR
- Stock Information
- Founded
- MCRB 2010
- RITR 2015
- Country
- MCRB United States
- RITR Hong Kong
- Employees
- MCRB N/A
- RITR N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- RITR
- Sector
- MCRB Health Care
- RITR
- Exchange
- MCRB Nasdaq
- RITR NYSE
- Market Cap
- MCRB 141.9M
- RITR 166.1M
- IPO Year
- MCRB 2015
- RITR 2024
- Fundamental
- Price
- MCRB $0.80
- RITR $2.78
- Analyst Decision
- MCRB Buy
- RITR
- Analyst Count
- MCRB 4
- RITR 0
- Target Price
- MCRB $5.63
- RITR N/A
- AVG Volume (30 Days)
- MCRB 844.5K
- RITR 185.0K
- Earning Date
- MCRB 03-04-2025
- RITR 02-15-2025
- Dividend Yield
- MCRB N/A
- RITR N/A
- EPS Growth
- MCRB N/A
- RITR N/A
- EPS
- MCRB N/A
- RITR 0.09
- Revenue
- MCRB $126,325,000.00
- RITR $47,948,887.00
- Revenue This Year
- MCRB N/A
- RITR N/A
- Revenue Next Year
- MCRB N/A
- RITR N/A
- P/E Ratio
- MCRB N/A
- RITR $30.89
- Revenue Growth
- MCRB 12856.41
- RITR 278.44
- 52 Week Low
- MCRB $0.54
- RITR $2.24
- 52 Week High
- MCRB $1.53
- RITR $8.75
- Technical
- Relative Strength Index (RSI)
- MCRB 46.38
- RITR N/A
- Support Level
- MCRB $0.81
- RITR N/A
- Resistance Level
- MCRB $0.84
- RITR N/A
- Average True Range (ATR)
- MCRB 0.04
- RITR 0.00
- MACD
- MCRB 0.00
- RITR 0.00
- Stochastic Oscillator
- MCRB 45.58
- RITR 0.00
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About RITR REITAR LOGTECH HLDGS LTD
Reitar Logtech Holdings Ltd provide one-stop solutions for logistics property operations in property development and redevelopment projects. It consists of two segments: construction management and engineering design services; and asset management and professional consultancy services in Hong Kong. Key revenue is generated from construction management and engineering design services.